ClinicalTrials.gg
CompletedNCT02390219Updated Dec 6, 2017Results posted

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

A Phase 3 interventional study of Lumacaftor and Ivacaftor in Cystic Fibrosis and Advanced Lung Disease, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 6 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-12-06.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
17th of 20
46 · median 66
Started
2015
with 2 others
Phase 3
10 of 20
none open now
Registered
12th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 17th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 3, and was the 12th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of LUM/IVA combination therapy in subjects 12 years and older with CF and advanced lung disease and who are homozygous for the F508del CFTR mutation

03

Conditions studied

  • Cystic Fibrosis
  • Advanced Lung Disease

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous for the F508del-CFTR mutation; historical genotype must be documented in the participant's source documents.
  • Percent predicted \<40 of adjusted for age, sex, and height at Screening

Exclusion criteria

Exclusion Criteria:

  • Participant currently receiving invasive mechanical ventilation.
  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
  • Any laboratory abnormalities at screening that would interfere with the study assessments or pose an undue risk for the subject
  • A 12-lead (ECG) demonstrating >450 msec at Screening
  • History of solid organ or hematological transplantation
  • History of alcohol or drug abuse in the past year
  • Ongoing or prior participation in an drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening.
  • Use of strong inhibitors, moderate inducers, or strong inducers of
  • Pregnant and nursing females: Females of must have a negative pregnancy test at Screening and Day 1.
  • Sexually active subjects of who are not willing to follow the requirements
  • Use of beta blockers or the equivalent at Screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Lumacaftor/Ivacaftor combination

    Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.

    Drug: Lumacaftor · Drug: Ivacaftor

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; event does not necessarily have a causal relationship with treatment. This includes any newly occurring event/previous condition that has increased in severity/frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event, which falls into any of the following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. TEAEs: AEs that started/ worsened on/after the start of study drug through the Safety Follow up Visit (4 weeks after the last dose of study drug). Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

    Time frame: Day 1 up to Week 28

Secondary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

    Time frame: Baseline, Up to Week 24

  2. Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

    Time frame: Baseline, Up to Week 24

  3. Duration For Which Participants Received Intravenous (IV) Antibiotics

    The duration for which participants received IV antibiotics for sinopulmonary signs and symptoms were reported. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

    Time frame: Baseline through Week 24

  4. Number of Hospitalizations

    Number of hospitalizations (all causes) through Week 24 was summarized. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

    Time frame: Baseline through Week 24

  5. Absolute Change From Baseline in Sweat Chloride at Average of Day 15 and Week 4

    Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. The average absolute change from baseline in sweat chloride was derived as: (Average of Day 15 and Week 4 value) minus Baseline value. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

    Time frame: Baseline, Day 15 and Week 4

  6. Absolute Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Domain Score Through Week 24

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

    Time frame: Baseline, Through Week 24

07

Results

Posted Nov 1, 2017

Participant flow

Participant flow — Overall Study
MilestoneLUM/IVA
Started46
Completed33
Not completed13
Withdrew: Death1
Withdrew: Physician decision1
Withdrew: Adverse event6
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up2
Withdrew: Other2

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; event does not necessarily have a causal relationship with treatment. This includes any newly occurring event/previous condition that has increased in severity/frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event, which falls into any of the following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. TEAEs: AEs that started/ worsened on/after the start of study drug through the Safety Follow up Visit (4 weeks after the last dose of study drug). Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

Time frame:
Day 1 up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
ParticipantsLUM/IVA
Participants with AEs43
Participants with SAEs18
SecondaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

Time frame:
Baseline, Up to Week 24
Reported as:
Least squares mean · Percent predicted of FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24
Percent predicted of FEV1LUM/IVA
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24-0.4 ± 0.7
SecondaryAbsolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

Time frame:
Baseline, Up to Week 24
Reported as:
Least squares mean · Liter (L)
Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24
Liter (L)LUM/IVA
Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Up to Week 24-0.02 ± 0.03
SecondaryDuration For Which Participants Received Intravenous (IV) Antibiotics

The duration for which participants received IV antibiotics for sinopulmonary signs and symptoms were reported. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

Time frame:
Baseline through Week 24
Reported as:
Mean · Days
Duration For Which Participants Received Intravenous (IV) Antibiotics
DaysLUM/IVA
Duration For Which Participants Received Intravenous (IV) Antibiotics11.38 ± 18.15
SecondaryNumber of Hospitalizations

Number of hospitalizations (all causes) through Week 24 was summarized. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

Time frame:
Baseline through Week 24
Reported as:
Number · Hospitalizations
Number of Hospitalizations
HospitalizationsLUM/IVA
Number of Hospitalizations23
SecondaryAbsolute Change From Baseline in Sweat Chloride at Average of Day 15 and Week 4

Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. The average absolute change from baseline in sweat chloride was derived as: (Average of Day 15 and Week 4 value) minus Baseline value. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

Time frame:
Baseline, Day 15 and Week 4
Reported as:
Mean · Millimoles per litre (mmol/L)
Absolute Change From Baseline in Sweat Chloride at Average of Day 15 and Week 4
Millimoles per litre (mmol/L)LUM/IVA
Absolute Change From Baseline in Sweat Chloride at Average of Day 15 and Week 4-16.4 ± 1.3
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Domain Score Through Week 24

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Results were reported as planned, as a combined single LUM/IVA arm irrespective of permitted dose modification.

Time frame:
Baseline, Through Week 24
Reported as:
Least squares mean · Units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Domain Score Through Week 24
Units on a scaleLUM/IVA
Absolute Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Domain Score Through Week 242.5 ± 1.7

Adverse events

Collected over Day 1 up to Week 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LUM/IVA1/46 (2.2%)18/46 (39.1%)43/46 (93.5%)
Most frequent serious events
Most frequent serious events
EventLUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations16/46
CoughRespiratory, thoracic and mediastinal disorders1/46
HaemoptysisRespiratory, thoracic and mediastinal disorders1/46
Respiration abnormalRespiratory, thoracic and mediastinal disorders1/46
NeuralgiaNervous system disorders1/46
PyrexiaGeneral disorders1/46
ArthralgiaMusculoskeletal and connective tissue disorders1/46
BacteraemiaInfections and infestations1/46
InfluenzaInfections and infestations1/46
PneumoniaInfections and infestations1/46
Most frequent other events
Showing 10 of 112
Most frequent other events
EventLUM/IVA
Respiration abnormalRespiratory, thoracic and mediastinal disorders25/46
CoughRespiratory, thoracic and mediastinal disorders21/46
DyspnoeaRespiratory, thoracic and mediastinal disorders20/46
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations20/46
Sputum increasedRespiratory, thoracic and mediastinal disorders13/46
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/46
FatigueGeneral disorders7/46
HaemoptysisRespiratory, thoracic and mediastinal disorders7/46
HeadacheNervous system disorders7/46
Nasal congestionRespiratory, thoracic and mediastinal disorders5/46

Baseline characteristics

Age, Continuous
Age, Continuous(years)LUM/IVA
Mean32.1 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)LUM/IVA
Female16
Male30
08

Study locations

6 sites
  • Denver, Colorado, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Saint Louis, Missouri, United States
  • Pittsburgh, Pennsylvania, United States
  • Houston, Texas, United States
09

References and documents

Publications

  • Taylor-Cousar JL, Jain M, Barto TL, Haddad T, Atkinson J, Tian S, Tang R, Marigowda G, Waltz D, Pilewski J; VX14-809-106 Investigator Group. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018 Mar;17(2):228-235. doi: 10.1016/j.jcf.2017.09.012. Epub 2017 Nov 8. PubMed 29126871 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2015
First posted
Mar 17, 2015
Start
Mar 2015
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results first posted
Nov 1, 2017
Last update
Dec 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02390219
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
Mar 2015
Primary completion
Oct 2016
Completion
Oct 2016
Results posted
Nov 1, 2017
Last update
Dec 6, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumacaftor

Start the discussion